-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 69c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)
-
-
-
-
-
-
-
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
-
-
-
-
-
-
-
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Misses Q2 EPS by 17c
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 11c
-
1,222,614 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

